METASTATIC RENAL CELL CARCINOMA

This early-phase trial tests the safety and best dose of combining two drugs—ziv-aflibercept and pembrolizumab—in people with advanced solid tumors that have spread. Ziv-aflibercept cuts off the tumor's blood supply, while pembrolizumab helps the immune system fight cancer. The s…

This study tests whether focused, high-dose radiation (SBRT) can control kidney cancer that has spread to a few spots in the body. The goal is to see if this approach can delay or avoid the need for systemic treatments like chemotherapy or immunotherapy. About 123 participants wi…

This study tests whether giving precise, high-dose radiation (SAbR) to tumors before standard treatment (immunotherapy or pills) helps people with kidney cancer that has spread to 2-5 places in the body live longer. About 472 adults with this type of advanced kidney cancer will t…

This early-stage study is testing whether giving two cancer drugs (cabozantinib and nivolumab) along with radiation therapy is safe for people with kidney cancer that has spread to the brain. Only 2 participants were enrolled to closely monitor side effects, especially those affe…

This study tests a new combination of three treatments—an immune-boosting injection (IL-2), targeted radiation, and the immunotherapy drug pembrolizumab—in adults with advanced lung, skin, kidney, or head and neck cancers that no longer respond to standard immunotherapy. The goal…

This early-phase study looks at whether adding a probiotic called CBM588 to the usual two-drug treatment (cabozantinib and nivolumab) can improve outcomes for people with advanced kidney cancer that has spread. The probiotic is meant to increase helpful gut bacteria, which may he…

This study tests whether adding the immunotherapy drug nivolumab before and after kidney cancer surgery can stop the cancer from returning. About 819 people with localized kidney cancer took part. The goal is to see if this approach improves how long patients stay cancer-free com…

This early-phase study tests a new treatment for people with advanced cancers that have not responded well to standard care. The treatment combines NBTXR3 (tiny particles injected into the tumor), radiotherapy, and an immunotherapy drug (anti-PD-1). The goal is to see if this tri…

This study tests a drug called adavosertib in 18 adults with advanced solid tumors that lack the SETD2 gene. The drug works by blocking enzymes that help cancer cells grow. Researchers want to see if it can shrink tumors or keep them stable for at least 6 months.

This early-stage trial aimed to test the safety and effectiveness of STIL101, a personalized cell therapy made from a patient's own tumor-fighting T cells, for several advanced cancers including pancreatic, colorectal, kidney, cervical, and melanoma. The treatment involved collec…

This study tests whether combining two drugs—axitinib (which blocks cancer cell growth) and nivolumab (which helps the immune system attack cancer)—works better than nivolumab alone for a rare type of kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial i…

This study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug works better at slowing cancer growth and has fewer side effects. About 32 par…

This study looks at whether keeping blood pressure very low (below 120 mmHg) is better than the usual target (below 140 mmHg) for people with advanced kidney or thyroid cancer who are starting certain targeted cancer drugs. The goal is to reduce the risk of heart and kidney probl…

This study tests whether combining evolocumab (a cholesterol drug) with nivolumab (an immunotherapy) can help control metastatic kidney cancer that hasn't responded to prior treatments. Ten adults with clear-cell kidney cancer are taking part. The main goals are to check safety a…

This study tests a drug called ceralasertib, either alone or combined with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, endometrial, and prostate cancers. The goal is to see if these combinations can shrink tumors or slow their gr…

This study tests a combination of three drugs (ixazomib, gemcitabine, and doxorubicin) in 30 people with a rare and aggressive kidney cancer that has spread. The goal is to see if the treatment can shrink tumors or stop them from growing. Participants receive the drugs in cycles,…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This study tests whether a smartphone app that teaches mindfulness can help people with metastatic kidney cancer feel better emotionally and improve their quality of life. About 21 adults with advanced kidney cancer who are on immunotherapy and have moderate to high fear of their…

This study was designed to see if limiting eating to a 10-hour window each day could help immunotherapy work better in people with advanced head and neck or kidney cancer. Researchers planned to compare outcomes in African American participants and others. The study was withdrawn…

This study follows about 468 people with metastatic kidney cancer to see how their treatment choices and quality of life change over time in real-world clinics and hospitals. Participants answer questionnaires about symptoms, side effects, and well-being. No new drugs are tested;…

This study watches how adults with advanced kidney cancer handle the drugs cabozantinib (alone or with nivolumab) as their first treatment. It does not test new treatments but tracks real-life side effects, dose changes, and treatment stops. The goal is to learn how these drugs a…